The Prognosis of Late Presenters in the Era of Highly Active Antiretroviral Therapy in Serbia
Open Access
- 28 October 2009
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Virology Journal
- Vol. 3 (1), 84-88
- https://doi.org/10.2174/1874357900903010084
Abstract
To examine the prognosis of patients who present with very advanced HIV-induced immunodeficiency, and their response to highly active antiretroviral therapy (HAART), a series of 101 treatment naïve patients from the Serbian cohort of HIV infected patients, who presented with a CD4 count of </= 50/microL before commencing HAART, was retrospectively analyzed and factors influencing response to HAART and survival investigated. After a mean of three years (range 1-9) of treatment with PI-based and/or NNRTI-based regimens, a favorable response was achieved in 54.5% of the patients, treatment failure occurred in 13.9%, while 31.7% had a dissociative immunological/virological response. The overall estimated survival was eight years. Achievement of undetectable viremia during treatment appeared life saving (OR = 42.5, 95% CI 7.1 - 251.9, P = 0.000, as was a rise in CD4 cell count to over 200/muL (OR = 6.4, 95% CI 1.2-31.8, P = 0.023). However, undetectable viremia was the single predictor of longer survival (OR = 42.5, 95% CI 7.1 - 251.9, P = 0.000), regardless of the level of immune reconstitution (log rank, P = 0.31). Late presenters had a high probability of developing the metabolic syndrome while on HAART, with a median time to hyperlipidemia and lypodystrophy of 5 and 6 years, respectively. We conclude that late presenters on HAART may have a good prognosis, a prerequisite for which is sustained undetectable viremia regardless of the immune recovery.Keywords
This publication has 23 references indexed in Scilit:
- Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studiesAIDS, 2007
- Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and MontenegroHIV Medicine, 2007
- Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment optionsAIDS Research and Therapy, 2007
- Immunological and virological responses to highly active antiretroviral therapy in a non‐clinical trial setting in a developing Caribbean countryHIV Medicine, 2006
- The prevalence and risk of immune restoration disease in HIV‐infected patients treated with highly active antiretroviral therapyHIV Medicine, 2005
- Temporal Trend and Factors Associated with Late HIV Diagnosis in Hong Kong, a Low HIV Prevalence LocalityAIDS Patient Care and STDs, 2003
- Rate, Causes, and Clinical Implications of Presenting with Low CD4+ Cell Counts in the Era of Highly Active Antiretroviral TherapyAIDS Research and Human Retroviruses, 2003
- Late diagnosis of HIV infection in the era of highly active antiretroviral therapyAIDS, 2002
- Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic populationAIDS, 2000
- Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapyAIDS, 1999